Summary
Polymorphic purity is a critical quality attribute for pharmaceutical products. Different polymorphs of the same API can have dramatically different solubility, dissolution rate, bioavailability, and stability. Unintended polymorphic transformations during manufacturing or storage can compromise product performance or lead to batch failures.
This application note demonstrates a validated XRPD method for quantification of polymorphic impurities in a finished tablet formulation. The method achieves LOD of 0.17% wt and LOQ of 0.5% wt for polymorphic contaminants in the presence of excipients, suitable for cGMP batch release testing.
Background & Regulatory Context
Why Polymorph Control Matters
Historical FDA cases of polymorph-related issues:
- Ritonavir (Norvir®): Form II appeared in marketed product, causing formulation failure
- Rotigotine patches: Crystal growth led to product recall
- Generic carbamazepine: Different polymorph led to bioavailability issues
Regulatory Requirements
- ICH Q6A: Polymorphic form must be controlled and specified
- USP<941>: XRPD recognized method for polymorph identification
- Ph.Eur<2.9.33>: Characterization of crystalline solids
- Stability studies: Monitor polymorphic changes during storage
Methods & Experimental Design
XRPD Measurement
Instrument Parameters
- X-ray sourceCu Kα
- InstrumentLaboratory XRPD at DANNALAB
- Angular Range0-40 deg 2θ
Calibration Approach
Sample matrix: Tablets ground and homogenized
Spiking levels: Different concentrations of polymorphic impurity prepared
Method: Single peak marker or full pattern approach
Validation Results
ICH-Compliant Validation Parameters
- SpecificityForm II peak uniquely resolved
- LinearityR² = 0.9985 (0.5-10% range)
- LOD0.17% wt (S/N = 3)
- LOQ0.50% wt (S/N = 10)
- Accuracy98-102% recovery
- Precision (repeatability)RSD = 3.2% at 1% level
- Intermediate precisionRSD = 4.8%
- Range0.5-10% validated
Method Performance
| Spiked Level | Measured (n=6) | Recovery | RSD |
|---|---|---|---|
| 0.5% (LOQ) | 0.51 ± 0.05% | 102% | 9.8% |
| 1.0% | 0.99 ± 0.03% | 99% | 3.2% |
| 2.0% | 2.01 ± 0.05% | 101% | 2.5% |
| 5.0% | 4.95 ± 0.10% | 99% | 2.0% |
| 10.0% | 9.88 ± 0.18% | 99% | 1.8% |
Figure 1. XRPD patterns showing detection and quantification of Form II polymorphic impurity at different concentration levels (0.5%, 1%, 2%, 5%, 10% wt) in finished drug product tablets containing predominantly Form I.
Batch Release Application
cGMP Deliverables
- QA-approved CoA: Certificate of Analysis for batch release
- Quantitative result: "Form II < 0.5% wt" (below LOQ = compliant)
- Acceptance criteria: NMT 2.0% wt Form II
- Raw data package: 21 CFR Part 11 compliant if required
- Method reference: Validated method SOP number provided
Typical Specification
Example Acceptance Criteria
- Primary polymorphForm I ≥ 98%
- Polymorphic impuritiesForm II ≤ 2.0% wt
- Detection limitLOD 0.17%, LOQ 0.50%
Conclusion
The quantification of low-level polymorph impurities within finished drug products presents analytical challenges related to the low concentration of API within the formulation and the necessity to quantify minor impurities against heavy placebo contribution. This application note demonstrates validated quantification methods for polymorphic impurity control.
Related Application Notes
Presentation
Download Presentation: XRPD Quantification of Polymorph Impurities (PDF)